Weekly Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings

June 27, 2018 - By Alice Reed

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
During 2018 Q1 the big money sentiment decreased to 1.51. That’s change of 0.15, from 2017Q4’s 1.66. 16 investors sold all, 49 reduced holdings as Halozyme Therapeutics, Inc. ratio turned negative. 56 rose positions while 42 funds bought positions. Funds hold 119.54 million shares thus 1.04% more from 2017Q4’s 118.31 million shares.
Rhumbline Advisers owns 124,081 shs. Moreover, Numerixs Inv Technology Inc has 0.13% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Citadel Limited reported 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Renaissance Technology Limited Liability Corp holds 0.02% or 893,400 shs in its capital. Btg Pactual Glob Asset Mgmt Ltd holds 33,365 shs or 0.18% of its capital. 160,173 are held by Guggenheim Ltd Co. Moreover, Prudential Financial has 0.04% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 1.40 million shs. Goldman Sachs Group Inc Inc holds 1.34M shs. Alps, a Colorado-based fund reported 214,857 shs. Essex Inv Mngmt Com Limited Liability Com owns 49,258 shs for 0.13% of their capital. California Employees Retirement System owns 195,400 shs or 0.01% of their US capital. Proshare Ltd Liability Corp accumulated 81,407 shs. Public Employees Retirement Association Of Colorado reported 26,722 shs. Nj State Employees Deferred Compensation Plan has invested 0.12% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Invesco Limited owns 4.23 million shs or 0.03% of their US capital.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 6 analysts cover Halozyme (NASDAQ:HALO). “Buy” rating has 3, “Sell” are 1, while 2 are “Hold”. (NASDAQ:HALO) has 50% bullish analysts. 8 are the (NASDAQ:HALO)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Monday, May 14 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Buy” rating by Canaccord Genuity. On Wednesday, January 24 the rating was maintained by Deutsche Bank with “Buy”. On Friday, May 11 the firm has “Underweight” rating given by Barclays Capital. On Wednesday, February 21 the rating was maintained by Canaccord Genuity with “Buy”. On Wednesday, February 21 the rating was maintained by JP Morgan with “Overweight”. On Thursday, February 22 the rating was maintained by BMO Capital Markets with “Market Perform”. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0

Ticker’s shares touched $17.95 during the last trading session after 0.22% change.Currently Halozyme Therapeutics, Inc. is uptrending after 46.03% change in last June 27, 2017. HALO has also 23,747 shares volume. HALO outperformed the S&P 500 by 33.46%.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The firm is worth $2.57 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.The P/E ratio is 37.63. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

There’s a significant Halozyme Therapeutics, Inc. (NASDAQ:HALO) news brought out by Globenewswire.com. It’s an article titled: “Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix …” on June 13, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.